Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00241423 · ClinicalTrials.gov registry record · Phase 2

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

A Phase 2 study of Type 2 Diabetes Mellitus, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target
2
Study locations

NCT00241423 is a Phase 2 study of Type 2 Diabetes Mellitus that has completed, run by AstraZeneca. The registered enrollment target is 30 participants, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00241423, a Phase 2 study of Type 2 Diabetes Mellitus, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to test the hypothesis that in patients with type 2 diabetes, the addition of exenatide will result in lower time-averaged serum glucose during a 24-hour period, compared with placebo.

Conditions Studied

Type 2 Diabetes Mellitus

Interventions

  • DRUG Placebo
  • DRUG exenatide

Study Locations (2)

District of Columbia

  • Research Site - Washington D.C.

Texas

  • Research Site - San Antonio

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2005-10
Est. Completion 2007-06
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00241423

The ClinicalTrials.gov registry entry for NCT00241423 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00241423 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Texas.

Frequently Asked Questions

What is clinical trial NCT00241423 about?

NCT00241423 is a clinical study titled "Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes". The purpose of this study is to test the hypothesis that in patients with type 2 diabetes, the addition of exenatide will result in lower time-averaged serum glucose during a 24-hour period, compared with placebo.

What is the current status of trial NCT00241423?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-10. Estimated completion is 2007-06.

What conditions does trial NCT00241423 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.

What interventions are being tested in trial NCT00241423?

The interventions under investigation include: Placebo (DRUG), exenatide (DRUG).

Who is sponsoring clinical trial NCT00241423?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00241423 being conducted?

This trial has 2 study locations across District of Columbia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes Mellitus

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.